Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 4/20 | 0.55 |
| ▸ | CTSS | P25774 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.53 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869829 | 1.00 | SLC1A3 (0.57) | SLC1A3SLC1A1CTSKCTSSCTSL | |
| SCHEMBL5869834 | 1.00 | SLC1A3 (0.57) | SLC1A3SLC1A1CTSKCTSSCTSL | |
| SCHEMBL11130487 | 1.00 | SLC1A3 (0.57) | SLC1A3SLC1A1CTSKCTSSCTSL | |
| SCHEMBL10349204 | 0.94 | SLC1A3 (0.54) | SLC1A3SLC1A1CTSKCTSSCTSL | |
| Hydrochloric Acid SCHEMBL10349013 | 0.93 | SLC1A3 (0.53) | SLC1A3SLC1A1CTSKCTSSCTSL | |
| SCHEMBL10706501 | 0.90 | CA5A (0.60) | CTSKCTSSCTSLCTSBCAPN1 | |
| SCHEMBL7356544 | 0.83 | CTSL (0.59) | CTSKCTSSCTSLCAPN1 | |
| SCHEMBL11131051 | 0.83 | CTSL (0.59) | CTSKCTSSCTSLCAPN1 | |
| SCHEMBL16269961 | 0.83 | SLC1A3 (0.60) | SLC1A3SLC1A1CPB1CPB2 | |
| SCHEMBL16269913 | 0.83 | SLC1A3 (0.60) | SLC1A3SLC1A1CPB1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | SLC1A3 1507/4885SLC1A1 1365/4885CTSK 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.